Can our genes help predict how women respond to ovarian cancer treatment?

Can our genes help predict how women respond to ovarian cancer treatment?
Ovarian cancer cells. Credit: Westmead Institute for Medical Research

Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

The research showed that the genes we inherit can have a significant impact on how the body processes chemotherapy drugs, which may lead to different clinical outcomes for ovarian .

Lead researcher, led by Professor Anna deFazio from the Westmead Institute for Medical Research and Westmead Hospital, said this discovery may help doctors predict which patients will respond positively to chemotherapy.

"Chemotherapy and surgery are the standard treatment for women with , but each patient responds differently.

"We wanted to know why some women respond very positively to treatment, while others suffer serious side effects, and some have a poor response," Professor deFazio explained.

"We set out to understand which genetic factors influence how a patient processes chemotherapy"

"Our research showed that a gene called ABCC2 plays a critical role in eliminating chemotherapy from the body. ABCC2 is a drug transporter, which means it pumps a variety of different substances out of cells.

"We found that variants of this gene are associated with high rates of drug elimination, which means they pump out of the body quickly and may cause the treatment to be less effective.

"This may explain why is an effective treatment for some women, but not for others," she said.

Professor deFazio said these latest research findings are an important step towards delivering better outcomes for patients.

"Now that we are beginning to understand the role of the ABCC2 gene, and other novel gene variants that were identified in this research, we can work towards developing personalised cancer treatment for patients," Professor deFazio concluded.

Ovarian cancer is the most lethal gynaecological cancer and ranks as the sixth most common cause of cancer-related death in women in the Western world.


Explore further

New ovarian cancer drug licensed for use

More information: Bo Gao et al, Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer, Scientific Reports (2018). DOI: 10.1038/s41598-018-19590-w
Journal information: Scientific Reports

Provided by Westmead Institute for Medical Research
Citation: Can our genes help predict how women respond to ovarian cancer treatment? (2018, February 15) retrieved 19 October 2019 from https://medicalxpress.com/news/2018-02-genes-women-ovarian-cancer-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
24 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more